The role of beta-blocker drugs in critically ill patients: a SIAARTI expert consensus statement.

Fabio Guarracino, Andrea Cortegiani, Massimo Antonelli, Astrid Behr, Giandomenico Biancofiore, Alfredo Del Gaudio, Francesco Forfori, Nicola Galdieri, Giacomo Grasselli, Gianluca Paternoster, Monica Rocco, Stefano Romagnoli, Salvatore Sardo, Sascha Treskatsch, Vincenzo Francesco Tripodi, Luigi Tritapepe
{"title":"The role of beta-blocker drugs in critically ill patients: a SIAARTI expert consensus statement.","authors":"Fabio Guarracino, Andrea Cortegiani, Massimo Antonelli, Astrid Behr, Giandomenico Biancofiore, Alfredo Del Gaudio, Francesco Forfori, Nicola Galdieri, Giacomo Grasselli, Gianluca Paternoster, Monica Rocco, Stefano Romagnoli, Salvatore Sardo, Sascha Treskatsch, Vincenzo Francesco Tripodi, Luigi Tritapepe","doi":"10.1186/s44158-023-00126-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The role of β-blockers in the critically ill has been studied, and data on the protective effects of these drugs on critically ill patients have been repeatedly reported in the literature over the last two decades. However, consensus and guidelines by scientific societies on the use of β-blockers in critically ill patients are still lacking. The purpose of this document is to support the clinical decision-making process regarding the use of β-blockers in critically ill patients. The recipients of this document are physicians, nurses, healthcare personnel, and other professionals involved in the patient's care process.</p><p><strong>Methods: </strong>The Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI) selected a panel of experts and asked them to define key aspects underlying the use of β-blockers in critically ill adult patients. The methodology followed by the experts during this process was in line with principles of modified Delphi and RAND-UCLA methods. The experts developed statements and supportive rationales in the form of informative text. The overall list of statements was subjected to blind votes for consensus.</p><p><strong>Results: </strong>The literature search suggests that adrenergic stress and increased heart rate in critically ill patients are associated with organ dysfunction and increased mortality. Heart rate control thus seems to be critical in the management of the critically ill patient, requiring careful clinical evaluation aimed at both the differential diagnosis to treat secondary tachycardia and the treatment of rhythm disturbance. In addition, the use of β-blockers for the treatment of persistent tachycardia may be considered in patients with septic shock once hypovolemia has been ruled out. Intravenous application should be the preferred route of administration.</p><p><strong>Conclusion: </strong>β-blockers protective effects in critically ill patients have been repeatedly reported in the literature. Their use in the acute treatment of increased heart rate requires understanding of the pathophysiology and careful differential diagnosis, as all causes of tachycardia should be ruled out and addressed first.</p>","PeriodicalId":73597,"journal":{"name":"Journal of Anesthesia, Analgesia and Critical Care (Online)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591347/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Anesthesia, Analgesia and Critical Care (Online)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s44158-023-00126-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The role of β-blockers in the critically ill has been studied, and data on the protective effects of these drugs on critically ill patients have been repeatedly reported in the literature over the last two decades. However, consensus and guidelines by scientific societies on the use of β-blockers in critically ill patients are still lacking. The purpose of this document is to support the clinical decision-making process regarding the use of β-blockers in critically ill patients. The recipients of this document are physicians, nurses, healthcare personnel, and other professionals involved in the patient's care process.

Methods: The Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI) selected a panel of experts and asked them to define key aspects underlying the use of β-blockers in critically ill adult patients. The methodology followed by the experts during this process was in line with principles of modified Delphi and RAND-UCLA methods. The experts developed statements and supportive rationales in the form of informative text. The overall list of statements was subjected to blind votes for consensus.

Results: The literature search suggests that adrenergic stress and increased heart rate in critically ill patients are associated with organ dysfunction and increased mortality. Heart rate control thus seems to be critical in the management of the critically ill patient, requiring careful clinical evaluation aimed at both the differential diagnosis to treat secondary tachycardia and the treatment of rhythm disturbance. In addition, the use of β-blockers for the treatment of persistent tachycardia may be considered in patients with septic shock once hypovolemia has been ruled out. Intravenous application should be the preferred route of administration.

Conclusion: β-blockers protective effects in critically ill patients have been repeatedly reported in the literature. Their use in the acute treatment of increased heart rate requires understanding of the pathophysiology and careful differential diagnosis, as all causes of tachycardia should be ruled out and addressed first.

β受体阻滞剂在危重患者中的作用:SIAARTI专家共识声明。
背景:β-阻滞剂在危重症患者中的作用已经得到了研究,在过去的二十年里,文献中反复报道了这些药物对危重症患者的保护作用数据。然而,科学学会对危重患者使用β-阻滞剂的共识和指南仍然缺乏。本文件旨在支持危重患者使用β-受体阻滞剂的临床决策过程。本文件的接受者是医生、护士、医护人员和其他参与患者护理过程的专业人员。方法:意大利麻醉、镇痛、复苏和重症监护学会(SIAARTI)选择了一个专家小组,并要求他们确定在危重成年患者中使用β-受体阻滞剂的关键方面。专家在这一过程中所遵循的方法符合修改后的德尔菲和兰德-UCLA方法的原则。专家们以资料性文本的形式提出了陈述和支持性理由。发言的全部清单都经过了盲目投票以达成共识。结果:文献检索表明,危重患者的肾上腺素能应激和心率加快与器官功能障碍和死亡率增加有关。因此,心率控制在危重患者的管理中似乎至关重要,需要仔细的临床评估,以鉴别诊断治疗继发性心动过速和治疗心律失常。此外,一旦排除了低血容量,感染性休克患者可考虑使用β受体阻滞剂治疗持续性心动过速。静脉应用应该是首选的给药途径。结论:β-受体阻滞剂对危重患者的保护作用在文献中有反复报道。它们在心率加快的急性治疗中的应用需要了解病理生理学和仔细的鉴别诊断,因为应首先排除并解决心动过速的所有原因。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.40
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信